Back Home About Us

HIV and Hepatitis C Highlights from AIDS 2014

Latest Positive Pulse Newsletter

Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss highlights from this summer's International AIDS Conference, the largest and most comprehensive global meeting on the medical, public health, and social aspects of HIV and AIDS.

Highlights of this overview include the HIV cascade of care, developments in antiretroviral therapy, pre-exposure prophylaxis (PrEP) and other HIV prevention news, and new hepatitis C treatment for people with HIV/HCV coinfection.

10/22/14

alt

IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower Viral Rebound After Stopping ART

TEXT

alt

Read more:

High Effectiveness Seen in English PrEP Trial, All Will Be Offered Truvada

An interim analysis of the English PROUD study data has shown that daily Truvada pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men (MSM) at high risk of infection. On this basis, the PROUD Trial Steering Committee has announced that participants currently on the deferred arm of the study will be offered the opportunity to begin PrEP ahead of schedule.

alt

Read more:

IDWeek 2014: NNRTIs and Protease Inhibitors Both Good for First ART, Channeling Affects Choices

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 last week in Philadelphia. A related study shed light on factors affecting choice of initial antiretroviral regimen.

alt

Read more:

Coverage of IDWeek 2014

HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.

Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.

Full listing of coverage by topic

IDWeek 2014 website

10/17/14

alt

IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems

Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.

alt

Read more:

October 15 is National Latino AIDS Awareness Day

October 15 is National Latino AIDS Awareness Day(NLAAD), an opportunity to raise awareness about HIV/AIDS among Latino and Hispanic people in the U.S. According to the Centers for Disease Control and Prevention (CDC), while Latinos/Hispanics make up approximately 16% of the total U.S. population, they accounted for about 21% of all new HIV infections in 2010. The incidence rate for Latinos is about 3 times higher than that of whites, with a majority of cases occurring among young men who have sex with men.

alt

Read more:

HIV Positive Stimulant Users Benefit from Antiretroviral Therapy

People with HIV who use methamphetamine or other stimulant drugs do well on antiretroviral therapy (ART) and appear not to be at greater risk than non-users for AIDS-related or all-cause death overall, but those who use stimulants more than half the time did have a higher risk of progression to AIDS or death, according to a study published in the September 30 Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

IDWeek 2014: Efavirenz Not Linked to Suicide in Analysis of Insurance Records

The non-nucleoside reverse transcriptase inhibitor efavirenz (Sustiva, also in the Atripla single-tablet regimen) was not associated with a higher rate of suicidal thoughts or attempts in an analysis conducted by manufacturer Bristol-Myers Squibb (BMS), researchers reported at the 2014 IDWeek meeting last week in Philadelphia.

alt

Read more: